What question did this study set out to answer?

This research aims to evaluate treatment outcomes and cardiopulmonary function in beta thalassemia patients with pulmonary hypertension (PH).

February 25, 2026

Pulmonary hypertension in beta thalassemia: a prospective cohort study on treatment outcomes and cardiopulmonary function.

Puntos clave

This research aims to evaluate treatment outcomes and cardiopulmonary function in beta thalassemia patients with pulmonary hypertension (PH).
Conducted a prospective cohort study focusing on beta thalassemia patients with PH.
Assessed the impact of vasodilatory treatment on cardiopulmonary metrics.
Measured outcomes such as 6-minute walk test (6MWT), proBNP levels, and E/e' ratio.
Vasodilatory treatment led to significant improvements in 6MWT performance.
ProBNP levels decreased, indicating better heart function.
E/e' ratio improved, suggesting enhanced right ventricular function.

Resumen

Repeated blood transfusions correlate with RV dysfunction in thalassaemia patients with PH. Vasodilatory treatment improves 6MWT, proBNP levels, and E/e' ratio, indicating RV function enhancement. This study underscores the importance of comprehensive management strategies for thalassaemia patients with PH to mitigate associated complications and improve outcomes.

Me gusta

Guardar

Me gusta

Guardar

Pulmonary hypertension in beta thalassemia: a prospective cohort study on treatment outcomes and cardiopulmonary function.

Puntos clave

Resumen

Cite This Study